[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100537980":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":46,"centralContacts":51,"locations":62,"responsibleParty":90,"collaborators":56,"id":92,"slug":93,"hasResults":94,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":56,"eligibilityCriteria":98,"healthyVolunteers":94,"sex":99,"minAge":100,"maxAge":56,"enrollmentInfo":101,"targetDuration":56,"studyType":104,"phases":105,"briefSummary":107,"conditions":108,"keywords":56,"overallStatus":65,"whyStopped":56,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":119},{"fullName":5,"class":6},"Il-Yang Pharm. Co., Ltd.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Ilaprazole 10 mg","EXPERIMENTAL","Take Ilaprazole 10 mg 1 tablet + Placebo of Lansoprazole 15 mg 1 capsule by mouth, with water, once daily.",[13,14],"Drug: Ilaprazole","Drug: Lansoprazole Placebo",{"label":16,"type":17,"description":18,"interventionNames":19},"Lansoprazole 15 mg","ACTIVE_COMPARATOR","Take Lansoprazole 15 mg 1 capsule + Placebo of Ilaprazole 10 mg 1 tablet by mouth, with water, once daily.",[20,21],"Drug: Lansoprazole","Drug: Ilaprazole Placebo",[23,29,34,40],{"type":24,"name":25,"description":9,"armGroupLabels":26,"otherNames":27},"DRUG","Ilaprazole",[9],[28],"Noltec(the brand name)",{"type":24,"name":30,"description":16,"armGroupLabels":31,"otherNames":32},"Lansoprazole",[16],[33],"Lanston(the brand name)",{"type":24,"name":35,"description":36,"armGroupLabels":37,"otherNames":38},"Ilaprazole Placebo","Placebo of Ilaprazole 10 mg",[16],[39],"Ilaprazole Placebo-matching tablet",{"type":24,"name":41,"description":42,"armGroupLabels":43,"otherNames":44},"Lansoprazole Placebo","Placebo of Lansoprazole 15 mg",[9],[45],"Lansoprazole Placebo-matching tablet",[47],{"name":48,"affiliation":49,"role":50},"JungSoo Song, M.D.","Chung-Ang University Hospital Center","PRINCIPAL_INVESTIGATOR",[52,58],{"name":53,"role":54,"phone":55,"phoneExt":56,"email":57},"JungHwa Hong, Master","CONTACT","+82.2.570.3777",null,"jhhong@ilyang.co.kr",{"name":59,"role":54,"phone":60,"phoneExt":56,"email":61},"JeongSu Wi, bachelor","+82.2.570.3778","jswi@ilyang.co.kr",[63,80],{"facility":64,"status":65,"city":66,"state":56,"zip":56,"country":67,"countryCode":56,"cosmosGeoPoint":68,"geoPoint":73,"contacts":74},"Chung Ang University Hospital","RECRUITING","Seoul","South Korea",{"type":69,"coordinates":70},"Point",[71,72],126.9784,37.566,{"lat":72,"lon":71},[75,78],{"name":64,"role":54,"phone":76,"phoneExt":56,"email":77},"+82-2-6299-2741","irb@cauhs.or.kr",{"name":79,"role":50,"phone":56,"phoneExt":56,"email":56},"Jungsu Song, Professor",{"facility":81,"status":65,"city":66,"state":56,"zip":56,"country":67,"countryCode":56,"cosmosGeoPoint":82,"geoPoint":84,"contacts":85},"Chung-Ang University Hospital",{"type":69,"coordinates":83},[71,72],{"lat":72,"lon":71},[86,89],{"name":87,"role":54,"phone":88,"phoneExt":56,"email":77},"Chung-Ang University Institutional Review Board","+82-2-6299-2738",{"name":79,"role":50,"phone":56,"phoneExt":56,"email":56},{"type":91,"investigatorFullName":56,"investigatorTitle":56,"investigatorAffiliation":56,"oldNameTitle":56,"oldOrganization":56},"SPONSOR","100537980","phase-3-study-to-evaluate-the-efficacy-and-safety-of-ilaprazole-10-mg-in-prevention-nsaids-associated-peptic-ulcer-100537980",false,"NCT06284876","Study to Evaluate the Efficacy and Safety of Ilaprazole 10 mg in Prevention NSAIDs Associated Peptic Ulcer","A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Ilaprazole 10 mg in Prevention NSAIDs Associated Peptic Ulcer","Inclusion Criteria:\n\n1. Adult males and females aged 19 years or older on the day of informed consent\n2. Subjects requiring continuous treatment or receiving treatment with NSAIDs\n3. Subjects with at least one of following peptic ulcer risk factors at the time of Screening\n4. Subjects who have provided voluntary informed consent for the study participation after the study is explained\n\nExclusion Criteria:\n\n1. Subjects with Gastroesophageal varices, Esophageal stricture or ulcerous stenosis, Gastrointestinal bleeding or perforation, Esophageal dysplasia and else based on the screening EGD results.\n2. Subjects with inflammatory bowel diseases, pancreatitis, pyloric obstruction, and primary esophageal motility disorder\n3. Subjects with confirmed history of malignancy within 5 years prior to Screening\n4. Positive human immunodeficiency virus (HIV) antigen\u002Fantibody at Screening","ALL","19 Years",{"count":102,"type":103},416,"ESTIMATED","INTERVENTIONAL",[106],"PHASE3","To demonstrate the non-inferiority of Ilaprazole 10 mg to the active control in prevention of NSAIDs-associated peptic ulcer, as assessed by the proportion of subjects with peptic ulcer by Week 24",[109],"Peptic Ulcer","2025-05-25",{"date":112,"type":113},"2025-05-30","ACTUAL",{"date":115,"type":113},"2024-07-23",{"date":117,"type":103},"2027-02-28",{"name":5,"class":6},2]